New Scientist Magazine Selects Advanced Cell Technology’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program as One of ‘10 Ideas That Will Shape the Year’

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, today announced that its iPS cell-derived human platelet program has been named as one of the “10 Ideas That Will Shape The Year” in the ‘Christmas and New Year Special’ issue of the New Scientist, widely considered to be one of the most influential science and technology news magazines in the world.

Back to news